- Home
- SUPV vs GERN Comparison
SUPV vs GERN Comparison
Compare SUPV & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- GERN
- Stock Information
- Founded
- SUPV 1887
- GERN 1990
- Country
- SUPV Argentina
- GERN United States
- Employees
- SUPV N/A
- GERN 229
- Industry
- SUPV Commercial Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SUPV Finance
- GERN Health Care
- Exchange
- SUPV Nasdaq
- GERN Nasdaq
- Market Cap
- SUPV 905.2M
- GERN 823.0M
- IPO Year
- SUPV 2016
- GERN 1996
- Fundamental
- Price
- SUPV $5.69
- GERN $1.31
- Analyst Decision
- SUPV Hold
- GERN Buy
- Analyst Count
- SUPV 3
- GERN 8
- Target Price
- SUPV $17.00
- GERN $3.71
- AVG Volume (30 Days)
- SUPV 1.8M
- GERN 6.6M
- Earning Date
- SUPV 08-13-2025
- GERN 11-06-2025
- Dividend Yield
- SUPV 3.16%
- GERN N/A
- EPS Growth
- SUPV N/A
- GERN N/A
- EPS
- SUPV 0.09
- GERN N/A
- Revenue
- SUPV $631,132,570.00
- GERN $164,447,000.00
- Revenue This Year
- SUPV $29.13
- GERN $175.15
- Revenue Next Year
- SUPV $31.07
- GERN $56.61
- P/E Ratio
- SUPV $14.12
- GERN N/A
- Revenue Growth
- SUPV N/A
- GERN 11877.20
- 52 Week Low
- SUPV $5.84
- GERN $1.09
- 52 Week High
- SUPV $19.75
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- SUPV 24.66
- GERN 44.35
- Support Level
- SUPV $5.84
- GERN $1.27
- Resistance Level
- SUPV $6.40
- GERN $1.52
- Average True Range (ATR)
- SUPV 0.53
- GERN 0.06
- MACD
- SUPV -0.20
- GERN -0.02
- Stochastic Oscillator
- SUPV 1.32
- GERN 18.00
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.